Among the antimicrobial proteins and peptides of humans is the cationic 55 kDa bactericidal/permeabilityincreasing protein (BPI), which possesses antibacterial, endotoxin-neutalizing and opsonic activity against Gram-negative bacteria. Although identified originally as an abundant constituent of neutrophil granules, we have recently identified functional expression of BPI by human mucosal epithelia. BPI expression was markedly up-regulated by exposure of epithelia to lipoxins, endogenous anti-inflammatory eicosanoids that are generated in vivo in the context of aspirin treatment (aspirin-triggered lipoxins). Epithelial BPI was found to be surface expressed and fully functional, as measured by antibacterial activity against Salmonella typhimurium as well as lipopolysaccharide (LPS; endotoxin)-neutralizing activity. These results suggest a role for BPI as an effector of epithelial antibacterial activity and as a modulator of epithelial responses to LPS. Both BPI and the lipoxins are currently the subject of intensive biopharmaceutical development, raising the possibility that therapeutic use of BPI or modulation of epithelial BPI expression may be a useful adjunctive therapy for conditions in which epithelial inflammation is associated with Gram-negative infections and/or endotoxin.
Bactericidal/permeability-increasing protein (BPI)
BPI is a 55 kDa cationic polypeptide that is among the antimicrobial proteins and peptides of neutrophil granules of humans, rabbits and cows [1] . It is also expressed to a lesser extent in eosinophils [2] and, as will be discussed in this review, was recently discovered to be a product of mucosal epithelial cells [3] . BPI's crystal structure reveals a boomerang-shaped bi-partite molecule [4] that includes a cationic, lysine-rich N-terminal half containing the antibacterial and lipopolysaccharide (LPS; endotoxin)-neutralizing activities of the molecule [5] and a C-terminal half that contributes to the opsonic activity of BPI [6] (Figure 1) .
A growing number of proteins with primary structural homology with BPI and roles in lipid recognition and host defence are being identified. The plasma LPS-binding protein (LBP) is a product of the liver that has a net anionic charge and serves to greatly amplify responses to LPS by delivering LPS monomers to a monocyte receptor complex containing CD14, MD2 and Toll-like receptor 4 (TLR4) [7, 8] . Whereas LBP recruits LPS monomers for delivery to CD14, BPI stabilizes LPS aggregates, thereby preventing LBP-mediated LPS monomer delivery [9] . Thus BPI and LBP are functionally antagonistic. It is the C-terminal domains of Key words: bactericidal/permeability-increasing protein (BPI), endotoxin, lipoxin, Gramnegative bacteria, mucosal epithelium. Abbreviations used: ATLa, 15-epi-16-(p-fluoro)-phenoxy-lipoxin A4; BPI, bactericidal/ permeability-increasing protein; LBP, lipopolysaccharide-binding protein; LPS, lipopolysaccharide; LXA4, lipoxin A4; PLUNC, palate, lung and nasal epithelium clone; TLR, Toll-like receptor. 1 To whom correspondence should be addressed (e-mail olevy@rics.bwh.harvard.edu).
LBP and BPI that determine the route and host responses to LPS complexes [10] . While LBP predominates in resting plasma, the higher affinity of BPI for LPS [11] , coupled with the greater concentration of BPI at neutrophil-rich inflammatory sites, favours BPI-mediated endotoxin neutralization [12] . In addition to BPI and LBP, humans express cholesteryl ester transfer protein and phospholipid transfer protein, two lipid transport proteins that also possess LPS-interactive properties [13] . Homologues of BPI/LBP have recently been described in the head kidney and liver of a teleost fish (rainbow trout), suggesting that the BPI/LBP family is evolutionarily conserved [14] .
BPI's high affinity for the lipid A region of LPS [15] targets its cytotoxic activity predominantly to Gram-negative bacteria. Binding of BPI to the outer membrane of Gramnegative bacteria is followed by a time-dependent penetration of the molecule to the bacterial inner membrane, where damage results in loss of membrane integrity, dissipation of electrochemical gradients and bacterial death [16] . BPI's actions are amplified by extracellular factors, including the complement system and secretory phospholipase A 2 [17] . Members of the defensin and cathelicidin antimicrobial peptide families synergistically enhance BPI's antibacterial activity [18] . Although the anti-infective properties of BPI are best defined with respect to Gram-negative bacteria, BPI congeners and BPI-derived peptides have also been shown to have activity against cell-wall-deficient Gram-positive bacteria [19] and fungal organisms [20, 21] .
BPI binds the lipid A region of LPS with high affinity [15, 22] and thereby prevents its interaction with other (proinflammatory) LPS-binding molecules, including LBP and The BPI molecule has a boomerang shape, composed of two structurally similar domains. The lysine-rich N-terminal half of the molecule is highly cationic and possesses both the antibacterial and the anti-endotoxin activities of the molecule. The hydrophobic N-terminal half contributes to the opsonic activity of BPI. Two apolar binding pockets, one located in each half of the molecule, are thought to play a role in binding LPS acyl chains.
CD14 [11] . Since BPI binds the lipid A region that is common to all LPSs, it is able to neutralize endotoxin from a broad array of Gram-negative pathogens [23, 24] . Thus BPI is capable of inhibiting all of the many pro-inflammatory activities of LPS, including induction of cytokine release, activation of the neutrophil oxidase enzyme, nitric oxide formation, etc. [22, 23, 25, 26] .
The opsonic activity of BPI occurs via binding of the N-terminal domain to Gram-negative bacteria and the promotion, via the C-terminal portion of BPI, of bacterial attachment to neutrophils and monocytes [6] . Whether such opsonic effects occur via ligand-receptor interactions between the C-terminal half of BPI and membrane receptors, or by other mechanisms, is unclear.
The selective and potent action of BPI against Gramnegative bacteria and their LPSs is fully manifest in biological fluids, including plasma, serum and whole blood [23, 24] . In multiple animal models of Gram-negative sepsis and/or endotoxaemia, administration of BPI congeners is associated with improved outcome [27, 28] . These properties have rendered BPI an attractive target for biopharmaceutical development [29] . Recombinant N-terminal proteins derived from BPI have proven safe and non-immunogenic in phase I trials [30] and have demonstrated potent anti-endotoxic activity in phase II trials [31, 32] . In a large, multinational phase III double-blind, placebo-controlled trial, adjunctive treatment of meningococcal sepsis with a recombinant 21 kDa modified fragment of human BPI was associated with reduced complications, including reduced limb amputation [33] . Additional indications for the use of BPI congeners are being actively explored.
Lipoxins
Although the inflammatory response is critical to host defence, it is also a potential threat if left unchecked. Endogenous down-regulatory mechanisms exist to limit inflammation after the initial response to the offending stimulus. By virtue of its anti-infective and LPS-neutralizing properties, BPI is a proximal anti-inflammatory effector. Among the endogenous anti-inflammatory lipid mediators are the lipoxins (lipoxygenase interaction products) -antiinflammatory eicosanoids that are produced from membrane arachidonic acid via transcellular biosynthesis. For example, the short-lived tetraene eicosinoid lipoxin A 4 (LXA 4 ) is produced at inflammatory sites by interactions of leucocytes with epithelial cells (Figure 2 ) or of neutrophils with platelets [34] . The G-protein-coupled LXA 4 receptor ALX-R is expressed on leucocytes and is inducible on epithelial and vascular endothelial cells by mediators found within the inflammatory milieu [35] . LXA 4 and synthetic stable congeners are capable of inhibiting a variety of leucocytemediated inflammatory pathways [36] . Little is known about the downstream transcriptional pathways that are activated upon ligation of the lipoxin receptor.
Of note, acetylsalicylic acid (aspirin) induces the formation of 'aspirin-triggered' lipoxins. Acetylsalicylic acid modulates the oxygenating function of cyclo-oxygenase-2 at inflammatory sites and thereby triggers the biosynthesis of the anti-inflammatory lipid 15-epi-lipoxin [35] . The targets of the anti-inflammatory activities of lipoxins include epithelia that express lipoxin receptors. 15-Epi-lipoxin downregulates epithelial cell function, and the congener 15-epi-16-(p-fluoro)-phenoxy-LXA 4 (ATLa) reduces dermal neutrophil infiltration and blocks inflammation-induced hyperproliferation [37] . Synthetic lipoxin congeners have been synthesized that have increased stability and high potency [38] (Figure 2 ). Such lipoxin congeners are currently under evaluation for their potential as novel topical, oral and systemic anti-inflammatory agents [37] [38] [39] .
Epithelial expression of BPI
Several of the antimicrobial proteins and peptides of neutrophil granules have now been identified also as products of epithelial cells [40] . Initial attempts to identify BPI in epithelial cells, employing acid extraction techniques that efficiently solubilize BPI from neutrophils [41] , failed to detect BPI-like antigenicity or bioactivity (G. Canny, O. Levy, C. N. Serhan and S. P. Colgan, unpublished work). Our group identified the expression of BPI in epithelial cells as a result of a transcriptional profiling approach designed to identify lipoxin-regulated genes [3] . Oral epithelial cells (KB cells) were exposed to 1 µM of the aspirin-triggered LXA 4 analogue ATLa for up to 8 h. Of the 7129 genes that were screened, 97 (1.4%) were induced by 3-fold or greater by ATLa, among them the BPI gene. Similar induction of BPI was noted in both columnar (e.g. T84 and Caco2) and squamous epithelia (e.g. KB and OKF6) cells. Confocal microscopy and immunoprecipitation of surface-labelled protein localized BPI to the epithelial cell surface.
The function of epithelial BPI was studied by employing a neutralizing goat polyclonal anti-BPI serum. Pre-exposure of epithelial cells to anti-BPI serum increased the LPSinduced epithelial expression of ICAM-1 (intercellular celladhesion molecule-1), whereas normal goat serum had no effect. These results suggest that epithelial BPI serves to dampen inflammatory responses to endotoxin. Similarly, the bactericidal activity of epithelial cells towards Salmonella typhimurium, but not towards the Gram-positive bacterium Enterococcus faecalis, was reduced by pre-exposure of the epithelial cells to anti-BPI serum.
Expression of BPI in native human tissues was demonstrated in vivo by immunohistological localization to human oesophageal (squamous) and colonic (columnar) biopsies. In oesophageal epithelium, a gradient of BPI expression was noted, with strong expression at the transition zone between the lamina propria and the epithelium, and decreasing expression towards the surface. In the colon, expression of BPI was focused in the crypt and villus epithelia. Interestingly, BPI mRNA has also been detected in human nasolacrimal duct epithelium [42] .
Our finding of BPI on epithelial surfaces raises two conceptual points. First, epithelia provide the initiation point for host-microbial interactions. While microbial-epithelial interactions are in some instances beneficial to the host, some degree of selectivity may be important for homoeostasis. Epithelial-expressed BPI could play such a role. BPI is remarkable for its potent (nanomolar) and selective bioactivity against Gram-negative bacterial species [43] . Moreover, the finding that functional BPI is expressed on the cell surface, and not as a soluble molecule, suggests that it could provide selective antibacterial and endotoxin-neutralizing activity at the surface of the epithelium. Secondly, a basic feature of many mucosal surfaces, particularly along the alimentary tract, is the presence of high concentrations of LPS. Recent studies have defined the existence of pro-inflammatory LPS receptors (e.g. CD14 and TLR4) on epithelial surfaces [44] , and previous work suggested epithelial cells can respond to endotoxin [45] . From this perspective, we speculate that endogenous mechanisms are likely to exist that dampen the aberrant activation of epithelial cells by LPS. BPI expression in native epithelia could provide an innate dampening mechanism against LPS, by effectively competing for the binding of endotoxin, thereby preventing or regulating endotoxin binding. Epithelial BPI may thereby contribute to the innate biochemical barrier characteristic of mucosal surfaces, while providing a degree of selectivity necessary for effective host responses (Figure 3) .
The BPI superfamily recently underwent a major expansion with the identification of identity with a murine epithelial-expressed gene named plunc (palate, lung and nasal epithelium clone) [46,46a,47] . The PLUNC family includes proteins with extended structures corresponding to holo-BPI (long or 'L'PLUNC), as well as smaller proteins with identity corresponding only to the N-terminal half of BPI (short or 'S'PLUNC). The primary amino acid sequences of the PLUNC proteins reveal substantial divergence in the Nterminal region, with greater identity (among the LPUNCS) in the region corresponding to the C-terminal half of BPI. Overall, the PLUNC family has modest amino acid sequence identity with BPI, but a very similar predicted fold and genomic organization [47] . Rat and human PLUNCs are secreted in nasal mucus, and rat PLUNC is up-regulated in the nasal respiratory epithelium after bulbectomy, suggesting roles in host defence after injury [48] .
Future research and clinical implications
The molecular pathway(s) by which ATLa induces BPI expression remain to be determined. As a major role of BPI is to neutralize endotoxin, it will be important to define the relative expression and transcriptional regulation of BPI and other (pro-inflammatory) LPS-interactive proteins that are known to be expressed in epithelial cells, including LBP [49, 50] , CD14 [51,51a] and TLR4 [52] . It will also be of interest to determine whether the opsonic activity of BPI [6] is also manifest in the epithelial cell setting. In addition, BPI (and its derivatives) exhibits anti-angiogenic properties [53] and is capable of inducing apoptosis in endothelial cells [54] . It is thus possible that induction of BPI may account in part for the anti-angiogenic activity of lipoxins [55] .
We have found that, in addition to the actions of BPI, ATLa-treated epithelial cells also demonstrate increased expression of several proteins with potential roles in host defence, including the broadly antimicrobial peptide human intestinal defensin 5 [56] and lysozyme (O. Levy, G. Canny, C. N. Serhan and S. P. Colgan, unpublished work). Since BPI can also act in synergy with other antimicrobial proteins and peptides, including defensins [18] , these findings indicate that lipoxin induction may serve to co-ordinate expression of these diverse host defence factors. Interestingly, lipoxin analogues effectively inhibited S. typhimurium-induced secretion of chemoattractants by epithelial cells [57] . In addition, administration of ATLa enhanced the resolution of inflammation induced by the dental pathogen Porphyromonas gingivalis in a murine air pouch model [58] . Future efforts will be directed towards determining to what extent the anti-inflammatory activities of lipoxins against inflammation induced by Gram-negative bacteria are attributable to induction of epithelial BPI expression. It will be of great interest to determine whether the related PLUNC proteins are lipoxin-inducible as well.
The demonstration that human mucosal epithelia can be induced to express functional BPI on their surface raises a number of important therapeutic possibilities. For example, Crohn's disease is characterized by recurrent bowel inflammation, and several lines of evidence suggest a pathophysiological role for endotoxin [59, 60] . Such studies raise the possibility that augmenting gut defence by increasing BPI levels at these mucosal sites, either by systemic intravenous administration of BPI or via lipoxin-induced augmentation of BPI expression [39] , might serve to neutralize endotoxin, thereby diminishing inflammatory disease. In support of this idea, it was shown recently that oral administration of lipoxin analogues significantly attenuated symptoms associated with colitis in a murine model [39] . Of note, ATLa-induced BPI expression was also demonstrated in pulmonary (A549) epithelial cells, suggesting that epithelial BPI may serve to dampen LPS-driven inflammatory responses in the lung. It has been demonstrated that the Pseudomonas aeruginosa isolated from the sputum of patients with cystic fibrosis synthesize LPS that possesses unusually high inflammatory activity [61] . This raises the possibility that therapeutic modulation of pulmonary epithelial BPI expression might serve to reduce LPS-driven inflammation in patients with cystic fibrosis. These are but some examples of how the discovery that human epithelial cells express BPI [3] opens the door to a host of exciting biomedical investigations.
